 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||
2 January 2007 | Volume 146 Issue 1 | Pages 25-33
Background: Rituximab, a monoclonal anti-CD20 antibody, is increasingly used to treat idiopathic thrombocytopenic purpura (ITP).
Purpose: To systematically review the literature on the efficacy and safety of rituximab for the treatment of adults with ITP.
Data Sources: MEDLINE, EMBASE, the Cochrane Library, abstracts from the American Societies of Hematology and Clinical Oncology annual meetings, and bibliographies of relevant articles and reviews were searched in duplicate until April 2006.
Study Selection: Descriptive and comparative studies in any language that met predefined inclusion criteria were eligible. Efficacy analysis was restricted to studies enrolling 5 or more patients.
Data Extraction: Platelet count response, toxicities, dose, previous treatments, baseline platelet count, duration of ITP, study design, and sources of funding were extracted in duplicate.
Data Synthesis: We identified 19 eligible reports on efficacy (313 patients) and 29 on safety (306 patients). Weighted means for complete response (platelet count > 150 x 109 cells/L) and overall response (platelet count > 50 x 109 cells/L) with rituximab were 43.6% (95% CI, 29.5% to 57.7%) and 62.5% (CI, 52.6% to 72.5%), respectively. Responses lasted from 2 to 48 months. Nearly all patients had received corticosteroids, and 53.8% had undergone splenectomy. Nine patients (2.9%) died.
Limitations: There were no controlled studies, and no studies met all criteria for study quality. Reported deaths could not necessarily be attributed to rituximab. Overall, the number of rituximab-treated patients with ITP reported in the literature is small.
Conclusions: Rituximab resulted in an overall platelet count response in 62.5% of adults with ITP. However, this finding derives from uncontrolled studies that also reported significant toxicities, including death in 2.9% of cases. These data suggest that providers should avoid indiscriminate use of rituximab and that randomized, controlled trials of rituximab for ITP are urgently needed.
Author and Article Information
From McMaster University and Juravinski Cancer Centre, Hamilton, Ontario, Canada; Insubria University, Varese, Italy; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Queen’s University, Kingston, Ontario, Canada; University of Waterloo, Waterloo, Ontario, Canada.
Acknowledgments: The authors thank the staff of the McMaster Transfusion Research Program for their administrative assistance with this research.
Grant Support: Dr. Arnold is a research fellow of the Canadian Institutes for Health Research and Canadian Blood Services; Dr. Crowther is a Career Investigator of the Heart and Stroke Foundation of Ontario; Dr. Cook is a Canada Research Chair; Dr. Fraser is a research fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada; Dr. Lim is the recipient of the ISTH Clinical Research Fellowship.
Potential Financial Conflicts of Interest: Consultancies: R.M. Meyer (Hoffmann-LaRoche, Canada); Honoraria: R.M. Meyer (Hoffmann-LaRoche, Canada); Grants received: D.M. Arnold (Hoffmann-LaRoche, Canada); Grants pending: D.M. Arnold (Roche Canada).
Corresponding Author: Donald M. Arnold, MD, McMaster University Health Sciences Center, Room 3N-43, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada; e-mail, arnold{at}mcmaster.ca.
Current Author Addresses: Dr. Arnold and Mr. Sigouin: McMaster University Health Sciences Center, Room 3N-43, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
Dr. Dentali: Department of Clinical Medicine, Insubria University, Viale Borri 57, Varese, Italy 21100.
Dr. Crowther and Dr. Lim: St. Joseph’s Hospital, 50 Charlton Avenue East, Room L-208, Hamilton, Ontario L8N 4A6, Canada.
Dr. Meyer: Clinical Trials Division, Cancer Research Institute, Queen’s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada.
Dr. Cook: University of Waterloo, 200 University Avenue West, Waterloo, Ontario N2L 3G1, Canada.
Dr. Fraser: Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario L8V 5C2, Canada. REVIEW
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. N. George Definition, diagnosis and treatment of immune thrombocytopenic purpura Haematologica, June 1, 2009; 94(6): 759 - 762. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood, May 14, 2009; 113(20): 4834 - 4840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Perreault and J. Burzynski Romiplostim: A novel thrombopoiesis-stimulating agent Am. J. Health Syst. Pharm., May 1, 2009; 66(9): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Letchumanan, H.-J. Ng, L.-H. Lee, and J. Thumboo A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus Rheumatology, April 1, 2009; 48(4): 399 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Rodeghiero, R. Stasi, T. Gernsheimer, M. Michel, D. Provan, D. M. Arnold, J. B. Bussel, D. B. Cines, B. H. Chong, N. Cooper, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group Blood, March 12, 2009; 113(11): 2386 - 2393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Bussel, D. J. Kuter, V. Pullarkat, R. M. Lyons, M. Guo, and J. L. Nichol Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP Blood, March 5, 2009; 113(10): 2161 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kelly, M. Gleeson, and P. T. Murphy Slow responses to standard dose rituximab in immune thrombocytopenic purpura Haematologica, March 1, 2009; 94(3): 443 - 444. [Full Text] [PDF]
|
|
|
|
|
|
F. Zaja and R. Fanin Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Author reply Haematologica, March 1, 2009; 94(3): 444 - 445. [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, A. Sarpatwari, J. B. Segal, J. Osborn, M. L. Evangelista, N. Cooper, D. Provan, A. Newland, S. Amadori, and J. B. Bussel Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review Blood, February 5, 2009; 113(6): 1231 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Burzynski New options after first-line therapy for chronic immune thrombocytopenic purpura Am. J. Health Syst. Pharm., January 15, 2009; 66(2_Supplement_2): S11 - S21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A Heemstra, R. E Toes, J. Sepers, A. M Pereira, E. P Corssmit, T. W J Huizinga, J. A Romijn, and J. W Smit Rituximab in relapsing Graves' disease, a phase II study Eur. J. Endocrinol., November 1, 2008; 159(5): 609 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. George and D. R. Terrell Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia Haematologica, October 1, 2008; 93(10): 1445 - 1449. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Warkentin and D. M. Arnold "Spare-spleen-uximab" for chronic ITP Blood, August 15, 2008; 112(4): 925 - 926. [Full Text] [PDF]
|
|
|
|
|
|
B. Godeau, R. Porcher, O. Fain, F. Lefrere, P. Fenaux, S. Cheze, A. Vekhoff, M.-P. Chauveheid, J. Stirnemann, L. Galicier, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study Blood, August 15, 2008; 112(4): 999 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Emilia, M. Luppi, M. Morselli, F. Forghieri, L. Potenza, and G. Torelli A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura Haematologica, July 1, 2008; 93(7): 1113 - 1115. [Full Text] [PDF]
|
|
|
|
|
|
F. Zaja, M. L. Battista, M. T. Pirrotta, S. Palmieri, M. Montagna, N. Vianelli, L. Marin, M. Cavallin, M. Bocchia, M. Defina, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica, June 1, 2008; 93(6): 930 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ruggeri, S. Fortuna, and F. Rodeghiero Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature Haematologica, January 1, 2008; 93(1): 98 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Berentsen Rituximab for the treatment of autoimmune cytopenias Haematologica, December 1, 2007; 92(12): 1589 - 1596. [Full Text] [PDF]
|
|
|
|
|
|
D. Provan, T. Butler, M. L. Evangelista, S. Amadori, A. C. Newland, and R. Stasi Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults Haematologica, December 1, 2007; 92(12): 1695 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Emilia, M. Luppi, P. Zucchini, M. Morselli, L. Potenza, F. Forghieri, F. Volzone, G. Jovic, G. Leonardi, A. Donelli, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles Blood, December 1, 2007; 110(12): 3833 - 3841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Semple Rituximab disciplines T cells, spares platelets Blood, October 15, 2007; 110(8): 2784 - 2785. [Full Text] [PDF]
|
|
|
|
|
|
R. Stasi, G. Del Poeta, E. Stipa, M. L. Evangelista, M. M. Trawinska, N. Cooper, and S. Amadori Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura Blood, October 15, 2007; 110(8): 2924 - 2930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Penalver and J. R. Cabrera Rituximab for Patients with Idiopathic Thrombocytopenic Purpura Ann Intern Med, August 21, 2007; 147(4): 281 - 281. [Full Text] [PDF]
|
|
|
|
 |
|
 Rituximab for Idiopathic Thrombocytopenic Purpura? Journal Watch (General), March 8, 2007; 2007(308): 6 - 6. [Full Text]
|
|
Read all Rapid Responses
